

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2022 October 21; 28(39): 5658-5783



**OPINION REVIEW**

- 5658 Risk factors for small intestinal adenocarcinomas that are common in the proximal small intestine  
*Fujimori S, Hamakubo R, Hoshimoto A, Nishimoto T, Omori J, Akimoto N, Tanaka S, Tatsuguchi A, Iwakiri K*

**REVIEW**

- 5666 COVID-19 and hepatorenal syndrome  
*Wu HHL, Athwal VS, Kalra PA, Chinnadurai R*
- 5679 Receptor of advanced glycation end-products axis and gallbladder cancer: A forgotten connection that we should reconsider  
*Rojas A, Lindner C, Schneider I, González I, Morales MA*
- 5691 Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations  
*Theofilis P, Vordoni A, Kalaitzidis RG*

**MINIREVIEWS**

- 5707 Pitfalls and promises of bile duct alternatives: A narrative review  
*Miyazawa M, Aikawa M, Takashima J, Kobayashi H, Ohnishi S, Ikada Y*
- 5723 SARS-CoV-2-induced liver injury: A review article on the high-risk populations, manifestations, mechanisms, pathological changes, management, and outcomes  
*Payus AO, Mohd Noh M, Azizan N, Muthukaruppan Chettiar R*

**ACADEMIC WRITING**

- 5731 All journals should include a correspondence section  
*Papanas N, Mikhailidis DP, Mukherjee D*

**ORIGINAL ARTICLE****Retrospective Cohort Study**

- 5735 Effects of COVID-19 on the liver: The experience of a single center  
*Liakina V, Stundiene I, Milaknyte G, Bytautiene R, Reivytyte R, Purnaite R, Urbanoviciute G, Kazenaite E*

**Retrospective Study**

- 5750 Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival  
*Weingarden AR, Gubatan J, Singh S, Balabanis TC, Patel A, Sharma A, Habtezion A*

**Observational Study**

- 5764** Serum metabolic profiling of targeted bile acids reveals potentially novel biomarkers for primary biliary cholangitis and autoimmune hepatitis

*Ma ZH, Wang XM, Wu RH, Hao DL, Sun LC, Li P, Niu JQ*

**ABOUT COVER**

Editorial Board of *World Journal of Gastroenterology*, Raquel Rocha, PhD, MD, Professor, Department of Sciences of Nutrition, School of Nutrition, Federal University of Bahia, Salvador 40.110-907, BA, Brazil. raquelrocha@ufba.br

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

**INDEXING/ABSTRACTING**

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports, Index Medicus, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJG as 5.374; IF without journal self cites: 5.187; 5-year IF: 5.715; Journal Citation Indicator: 0.84; Ranking: 31 among 93 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG's CiteScore for 2021 is 8.1 and Scopus CiteScore rank 2021: Gastroenterology is 18/149.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Yi-Xuan Cai*, Production Department Director: *Xiang Li*, Editorial Office Director: *Jia-Ru Fan*.

**NAME OF JOURNAL**

*World Journal of Gastroenterology*

**ISSN**

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

**LAUNCH DATE**

October 1, 1995

**FREQUENCY**

Weekly

**EDITORS-IN-CHIEF**

Andrzej S Tarnawski

**EDITORIAL BOARD MEMBERS**

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

**PUBLICATION DATE**

October 21, 2022

**COPYRIGHT**

© 2022 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

## SARS-CoV-2-induced liver injury: A review article on the high-risk populations, manifestations, mechanisms, pathological changes, management, and outcomes

Alvin Oliver Payus, Malehah Mohd Noh, Nornazirah Azizan, Raman Muthukaruppan Chettiar

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:** Invited article; Externally peer reviewed

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Floreani A, Italy; Hernandez-Caballero A, Mexico; Nooripour R, Iran

**Received:** July 16, 2022

**Peer-review started:** July 16, 2022

**First decision:** August 19, 2022

**Revised:** August 24, 2022

**Accepted:** October 10, 2022

**Article in press:** October 10, 2022

**Published online:** October 21, 2022



**Alvin Oliver Payus, Malehah Mohd Noh,** Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu 88400, Sabah, Malaysia

**Nornazirah Azizan,** Department of Pathobiology and Medical Diagnostic, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu 88400, Malaysia

**Raman Muthukaruppan Chettiar,** Department of Medicine, Hospital Queen Elizabeth I, 13a, Jalan Penampang, Kota Kinabalu 88200, Malaysia

**Corresponding author:** Alvin Oliver Payus, MD, MRCP, Senior Lecturer, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Jalan UMS, Kota Kinabalu 88400, Sabah, Malaysia. [dralvinpayus@ums.edu.my](mailto:dralvinpayus@ums.edu.my)

### Abstract

The novel coronavirus disease 2019 is an infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and was declared a global pandemic with more than 500 million reported cases and more than 6 million deaths worldwide to date. Although it has transitioned into the endemic phase in many countries, the mortality rate and overall prognosis of the disease are still abysmal and need further improvement. There has been evidence that shows the significance of SARS-CoV-2-related liver injury. Here, we review the literature on the various spectrum of SARS-CoV-2 infection-induced liver injury and the possible mechanisms of damage to the hepatobiliary system. This review aimed to illustrate the latest understanding regarding SARS-CoV-2-induced liver injury including the high-risk populations, the characteristic clinical manifestations, the possible pathogenic mechanism, the pathological changes, the current suggestions for clinical treatment for various spectrum of populations, and the prognosis of the condition. In conclusion, SARS-CoV-2 patients with a liver injury warrant close monitoring as it is associated with the more severe and poorer outcome of the infection.

**Key Words:** COVID-19; SARS-CoV-2; Pandemic; Liver injury; Pandemics; Prognosis

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** There are several reviews in the literature that discuss the pathophysiology, management, and outcomes of liver injury in coronavirus disease 2019 (COVID-19). Here, we reviewed the current understanding on various aspects of COVID-19-related liver injury, including the high-risk populations, the characteristic clinical manifestations, the possible pathogenic mechanism, the pathological changes, the current suggestions for clinical treatment for the spectrum of populations, and the prognosis of the condition.

**Citation:** Payus AO, Mohd Noh M, Azizan N, Muthukaruppan Chettiar R. SARS-CoV-2-induced liver injury: A review article on the high-risk populations, manifestations, mechanisms, pathological changes, management, and outcomes. *World J Gastroenterol* 2022; 28(39): 5723-5730

**URL:** <https://www.wjgnet.com/1007-9327/full/v28/i39/5723.htm>

**DOI:** <https://dx.doi.org/10.3748/wjg.v28.i39.5723>

## INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the name given to the newly emerged zoonotic virus that causes coronavirus disease 2019 (COVID-19)[1]. It was first reported in Wuhan, China on December 29, 2019 and was declared a global pandemic on March 11, 2020[2]. SARS-CoV-2 is an enveloped, single-stranded positive-sense RNA genome virus that harbors the largest genome among currently known RNA viruses, with a genome length of around 26 to 32 kb. It has an oval shape and an average size of 100 nm in diameter. Electron microscopy revealed large club-shaped spikes of glycoprotein membrane on the viral surface making the viral particles appear like a typical crown-like shape[3].

COVID-19 is a syndrome with various systemic and respiratory symptoms such as fever, fatigue, dry cough, and breathing difficulties. It can be critical, causing severe pneumonia and cardiorespiratory failure that requires specialized management in intensive care units[4]. SARS-CoV-2 can also affect other systems, namely the nervous system causing headache, anosmia, paresthesia, and altered consciousness[5]. Abnormal liver function parameters are commonly found in patients with SARS-CoV-2 infection, indicating that SARS-CoV-2 infection is associated with liver injury and even failure. Apart from that, several studies suggested that liver injury has a significant role in determining the severity and mortality rate of the disease. Considering the ongoing global threat of SARS-CoV-2 infection and the necessity to improve the prognosis of the disease, the treating physicians need to be aware of the association and significance of SARS-CoV-2 infection-related liver injury not only for the severity of the disease but also for the mortality rate and prognosis as a whole. Therefore, this review aimed to elucidate the importance of hepatobiliary involvement in SARS-CoV-2 infections and provide helpful information for managing the condition and improving the overall prognosis of the disease.

## HIGH RISK POPULATIONS OF SARS-COV-2-INDUCED LIVER INJURY

Since the beginning of the pandemic, it was reported that patients with severe SARS-CoV-2 infection tended to develop liver injury compared to mild infection. Cai *et al*[6] reported that male patients of older age and higher body mass index have a higher tendency to develop liver injury during the course of the disease. A similar finding was seen in a study on 79 non-hospitalized SARS-CoV-2 patients by Xie *et al*[7], who reported that liver injury was more common among male patients. The authors also said that patients with an underlying severe chronic lung disease have a higher rate of liver injury, which was also reported by Zhang *et al*[8]. Cai *et al*[6] and Singh and Khan[9] both found that liver injury was more common among patients with underlying liver disease. According to Da *et al*[10], the common etiology of chronic liver disease that is prone to developing worsening liver injury during the infection is alcohol-related liver disease. Patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis are usually associated with additional metabolic risk factors, such as obesity, that can increase the susceptibility to the infection and is commonly associated with a more severe presentation[11].

There has been significant concern about the increased susceptibility to SARS-CoV-2 infection among solid organ transplant recipients. In a systematic review by Piedade and Pereira[12], patients with liver transplant were not associated with an increased risk of SARS-CoV-2 infection. The risk is highly dependent on the sex, age, body mass index, history of hepatocellular carcinoma, and the immunosuppression drug dose of the patient. However, the prevalence of severe infection was higher among liver transplanted patients. A study by Becchetti *et al*[13] found that alterations in liver enzymes among liver transplanted patients with SARS-CoV-2 occurs more commonly among hospitalized patients. In addition, Ali Malekhosseini *et al*[14] showed that the admission rate of liver transplanted patients to the intensive care unit was as high as 33.3%.

No evidence shows that pregnancy increases susceptibility to SARS-CoV-2-induced liver injury. Nevertheless, a retrospective cohort study involving 122 pregnant patients with confirmed SARS-CoV-2 infection by Can *et al*[15] found that 13.9% developed an abnormal liver function that was generally mild, where most of them were critically ill and had a longer stay in the hospital compared to the normal liver function group.

## THE CHARACTERISTIC MANIFESTATIONS OF SARS-COV-2-INDUCED LIVER INJURY

The most common manifestations of SARS-CoV-2 induced liver injury was the elevation of liver enzymes, such as alanine transaminase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase, and alkaline phosphatase. In a meta-analysis completed in the first few months of the pandemic by Cai *et al*[6], about 25% of SARS-CoV-2 patients had increased liver enzyme levels, which showed a direct association with the disease activity. The prevalence of increased AST was higher than ALT levels and was positively correlated with the severity of cases, where the level was higher in patients with severe cases[7,8,15]. Lei *et al*[16] reported a significant association between inpatient mortality in SARS-CoV-2 infected patients and liver injury based on liver enzymes, specifically AST elevation.

In a study on 417 SARS-CoV-2 infected patients by Cai *et al*[6], 41.0% of patients had abnormal liver tests, and 5.0% had liver injury upon presentation to the hospital. Throughout hospitalization, 76.3% developed some form of abnormal liver function, and it was high enough to be considered liver injury in 21.5% of patients. A similar finding was reported by Fan *et al*[17], who conducted a retrospective single center study on 148 patients with SARS-CoV-2 infection, where 37.2% had an abnormal liver function at hospital admission. Patients with the abnormal liver function were also found to have an extended hospital stays. A retrospective study of 79 patients with SARS-CoV-2 by Xie *et al*[7] found that patients with an abnormal liver test had an extended stay in the hospital.

Phipps *et al*[18] reported that 21.0% of 2273 patients with SARS-CoV-2 infection had a moderate liver injury, which was defined as elevated liver enzymes two to five times above the upper limit of normal, and 6.4% had severe liver injury, which was defined as liver enzymes more than five times the upper limit of normal. In this study, 69% of the patients with liver injury required intensive care unit care. The reports also mentioned that severe liver injury was associated with elevated inflammation markers, including ferritin and interleukin 6 (IL-6).


## PROPOSED PATHOPHYSIOLOGICAL MECHANISM OF SARS-COV-2-INDUCED LIVER INJURY

The exact pathophysiological mechanism of SARS-CoV-2-induced liver injury is still poorly understood, but evidence has shown it to be multifactorial (as shown in Figure 1). One of the factors is direct invasion of SARS-CoV-2, which has been suggested in several studies. The primary receptor for SARS-CoV-2 cellular entry is the angiotensin-converting enzyme 2 (ACE2) receptors, which are found not only in the lung parenchyma but also in other parts of the body[19], such as the brain[5], gastrointestinal tract, biliary tree, and liver epithelia[20]. Zhou *et al*[21] stated that SARS-CoV-2 patients with gastrointestinal symptoms had higher AST and ALT levels, which reflected that ACE2 receptor was expressed within the gastrointestinal tract and the biliary tree. However, even though the ACE2 receptor is expressed more within the biliary tree than the liver parenchyma, most studies showed a predominant pattern of parenchymal liver injury based on the elevated levels of AST and ALT rather than the damage to the bile ducts, which was reflected by increased gamma-glutamyl transferase and alkaline phosphatase[22].

Wu *et al*[23] found that almost 50% of SARS-CoV-2 infected patients who recovered from the disease had persistent virus shedding in their fecal specimens for more than 10 d after viral detection in respiratory tract samples became negative. This may further support the possibility of viral replication in the hepatobiliary system. Similarly, the previous SARS-CoV strains that caused an outbreak from 2002 to 2004 have also been shown to directly injure the liver parenchyma causing lobular inflammation and apoptosis of hepatocytes[24].

Apart from the direct viral-induced hepatocytotoxic hypothesis, autoinflammatory mediated injury to the liver is another plausible explanation. Immune dysregulation can occur in severe SARS-CoV-2 infection, which the overactivation of the immune system will lead to systemic hyperinflammation in extreme conditions. This condition is called 'cytokine storm syndrome', which is a phenomenon that will not only cause pulmonary inflammation but also multiorgan involvement, including the nervous system causing encephalitis[25] and peripheral neuritis[26] and the liver causing acute hepatitis and even failure[27,28].

Drug-induced liver injury is also common in SARS-CoV-2 patients, as the medications used to treat the infection can be hepatotoxic. These include lopinavir/ritonavir, remdesivir, tocilizumab, and others



**Figure 1 Possible pathophysiological mechanisms of liver injury induced by severe acute respiratory syndrome coronavirus 2 infection.**  
ACE 2: Angiotensin-converting enzyme 2.

[29]. A study of 148 cases of SARS-CoV-2 infected patients in Shanghai by Li *et al*[30] found that the utilization rate of lopinavir/ritonavir among patients with abnormal liver function was higher than the patients with normal liver function. There was no significant difference in the pre-hospital medication between the two groups of patients. The exact mechanism of how lopinavir/ritonavir induces liver injury is still uncertain, but there is evidence that it activates the endoplasmic reticulum stress pathway in the liver and induces hepatocytes apoptosis[31].

Ritonavir is also widely metabolized by the liver through the cytochrome P450 system, where the production of toxic intermediates of any drugs that are metabolized by the system will have the potential of causing liver injury[32]. Tocilizumab, which is an IL-6 inhibitor that is used to reduce overactive inflammation, has been reported to cause drug-induced liver injury and liver failure, which in some cases requires a liver transplant[33]. The exact mechanism is still unknown but may be due to its inhibitory effect on the IL-6 pathway, which is essential for liver regeneration.

SARS-CoV-2 patients with underlying chronic liver diseases are more likely to suffer from liver injury. This may suggest that SARS-CoV-2 infection can aggravate underlying liver diseases. In addition, there is a possibility that the liver damage may be caused by the viral reactivation of existing liver diseases in SARS-CoV-2 infection. Some biological medications such as tocilizumab and baricitinib may cause reactivation of viral hepatitis B, which causes deterioration of liver function[34].

Another simpler hypothesis is that prolonged hypoxia and tissue ischemia in critically ill SARS-CoV-2 patients who suffer from severe pneumonia and acute respiratory distress syndrome can also be one of the mechanisms of liver injury and even failure[35]. This occurs due to prolonged tissue hypoperfusion leading to ischemia, including in the liver. The anaerobic metabolism and lactic acidosis will further depress the cardiorespiratory effort, which will cause the continuation of the vicious circle[36].

## PATHOLOGICAL CHANGES IN SARS-COV-2-INDUCED LIVER INJURY

The first post-mortem autopsy on a patient who succumbed to SARS-CoV-2 infection was reported by Xu *et al*[37]. The liver histology showed a moderate degree of microvesicular steatosis with mild lobular and portal vein activity in the study. Ji *et al*[38] reported overactivation of T cells, suggesting viral-induced cytotoxic T cell liver damage. Liu *et al*[39] described various hepatic lesions, including focal lobular necrosis, lobular lymphocytic and monocytic infiltration, ballooning degeneration of liver cells, and sinusoidal congestion with microthrombosis. A study on 48 liver autopsies by Sonzogni *et al*[40] reported focal portal and lobular lymphocytic infiltrates with multiple vascular changes, which are suggestive of hepatic vascular involvement.

Tian *et al*[41] also reported a similar autopsy finding of mild lobular lymphocytic infiltration, with sinusoidal expansion of the central lobule and patchy necrosis in the periportal and centrilobular areas. There was no significant inflammatory cell infiltration around the portal tracts, which is consistent with the mode of acute liver injury. Autopsy reports on 7 SARS-CoV-2 infected patients who died noted multiple platelet-fibrin microthrombi in the hepatic sinusoids[42]. Wang *et al*[43] and Wang *et al*[44]

reported massive hepatic apoptosis, microvesicular steatosis, and inflammatory cell infiltration over the portal systems. In addition, there was a large amount of viral SARS-CoV-2 RNA titers detected in the liver *via* reverse transcriptase-polymerase chain reaction[41,45].

## CURRENT MANAGEMENT OF SARS-COV-2-INDUCED LIVER INJURY IN VARIOUS POPULATIONS

Liver injury is a severe complication of SARS-CoV-2 infection and can significantly affect the outcome of the patient. Multiple studies have suggested regular monitoring of liver function parameters in SARS-CoV-2-infected patients. Based on the consensus statement of the American Association for the Study of Liver Diseases[46], it is recommended to consider etiologies outside SARS-CoV-2, such as other viral hepatitis. This has been proven in a case reported by Hambali *et al*[47], where a patient with SARS-CoV-2 infection presented with abnormal liver function and high IL-6, which was due to hepatocellular carcinoma. It is also essential to consider other indirect causes of liver injury such as myositis, cardiac injury, ischemia, and cytokine release syndrome. Patients with liver enzymes more than five times the upper limit of normal may be excluded but not contraindicated from using medications such as remdesivir, tocilizumab, and hydroxychloroquine. Every patient receiving the medications, especially remdesivir and tocilizumab should be regularly monitored for liver biochemical indicators regardless of baseline values. It should not be assumed that patients with autoimmune hepatitis and liver transplantation have a sudden onset of disease or acute cellular rejection without biopsy confirmation. Patients who are immunocompromised or are treated with immunosuppressive drugs should be considered at increased risk for SARS-CoV-2 infection and should be prioritized for testing[46].

SARS-CoV-2-infected patients with ongoing antiviral treatment for hepatitis B or C should be continued, but the initiation of antiviral treatment for hepatitis C may need to be delayed. Patients with an underlying liver disease requiring immunosuppressants should be continued in cases of mild infection, but in moderate to severe infection, the treatment dosage of calcineurin inhibitors should be reduced. The position statement from the European Association for the Study of the Liver-European Society of Clinical Microbiology and Infectious Diseases recommended that the dose of immunosuppressant drugs can be adjusted according to antiviral treatment regimens because the drugs in both regimens will likely interact with each other[48].

## THE OUTCOME OF SARS-COV-2-INDUCED LIVER INJURY AND PREDICTORS OF INFECTION SEVERITY

The biomarkers of liver injury were significantly higher in severe cases of SARS-CoV-2 infection. In a meta-analysis by Henry *et al*[49], the severity and mortality rate of SARS-CoV-2 infection was related to the biomarkers of liver functions, which suggests that liver injury has a strong correlation with the severity of SARS-CoV-2 infection. A retrospective study that compared the clinical spectrum between patients with and without liver injury by Xie *et al*[7] found the hospitalization time was significantly longer in patients with liver injury. Lei *et al*[16] reported that abnormal AST in SARS-CoV-2 infection was associated with a higher risk of death during hospitalization than other indicators of liver injury.

Kulkarni *et al*[50] stated that the severity of elevated liver enzyme markers determined the outcome of SARS-CoV-2 infection, with the incidence of liver injury as high as 58%-78% among the death cases. A multicenter study involving 2780 SARS-CoV-2 infected patients by Singh and Khan[9] found that patients with underlying liver disease had higher mortality and hospitalization. In addition to the abnormal liver biochemistry, hypoalbuminemia during the illness is an important indicator of the severity of the SARS-CoV-2 infection. Both studies by Gong *et al*[51] and Huang *et al*[52] showed that hypoalbuminemia was associated with severe infection and an independent risk factor for death.

## CONCLUSION

In conclusion, this review illuminated the significance of liver injury in SARS-CoV-2 infection based on the descriptions from the scientific literature. Although it is common and mild in the majority of cases, it is a strong predictor of the severity and a significant risk factor for the mortality rate of the disease, especially if it is associated with male sex, older age, the presence of other comorbidities or underlying chronic liver disease, and in severe respiratory symptoms. Therefore, it is prudent to monitor SARS-CoV-2-infected patients with liver injury and to individualize treatment for patients with an underlying disease who developed liver injury to improve the prognosis by delivering the appropriate management.

## ACKNOWLEDGEMENTS

The authors would like to thank all who were involved in writing this review article.

## FOOTNOTES

**Author contributions:** Payus AO designed the study, prepared the figure, and performed the majority of the writing; Azizan N provided input for the article and contributed to writing; Mohd Noh M and Muthukaruppan Chettiar R were both supervisors and contributed to the final revision of the manuscript; and all authors have read and approved the final manuscript.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** Malaysia

**ORCID number:** Alvin Oliver Payus 0000-0003-4675-103X; Malehah Mohd Noh 0000-0002-8166-7119; Nornazirah Azizan 0000-0002-5831-3734; Raman Muthukaruppan Chettiar 0000-0003-1506-6021.

**S-Editor:** Wang JJ

**L-Editor:** Filipodia

**P-Editor:** Wang JJ

## REFERENCES

- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020; **382**: 727-733 [PMID: 31978945 DOI: 10.1056/NEJMoa2001017]
- Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med* 2020; **382**: 1199-1207 [PMID: 31995857 DOI: 10.1056/NEJMoa2001316]
- Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. *Virol J* 2019; **16**: 69 [PMID: 31133031 DOI: 10.1186/s12985-019-1182-0]
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506 [PMID: 31986264 DOI: 10.1016/S0140-6736(20)30183-5]
- Payus AO, Liew Sat Lin C, Mohd Noh M, Jeffree MS, Ali RA. SARS-CoV-2 infection of the nervous system: A review of the literature on neurological involvement in novel coronavirus disease-(COVID-19). *Bosn J Basic Med Sci* 2020; **20**: 283-292 [PMID: 32530389 DOI: 10.17305/bjbm.2020.4860]
- Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y, Liu Y, He Q, Chen J, Liu L, Xu L. COVID-19: Abnormal liver function tests. *J Hepatol* 2020; **73**: 566-574 [PMID: 32298767 DOI: 10.1016/j.jhep.2020.04.006]
- Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. *Liver Int* 2020; **40**: 1321-1326 [PMID: 32239591 DOI: 10.1111/liv.14449]
- Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. *Liver Int* 2020; **40**: 2095-2103 [PMID: 32239796 DOI: 10.1111/liv.14455]
- Singh S, Khan A. Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study. *Gastroenterology* 2020; **159**: 768-771.e3 [PMID: 32376408 DOI: 10.1053/j.gastro.2020.04.064]
- Da BL, Im GY, Schiano TD. Coronavirus Disease 2019 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol-Associated Liver Disease. *Hepatology* 2020; **72**: 1102-1108 [PMID: 32369624 DOI: 10.1002/hep.31307]
- Zheng KI, Gao F, Wang XB, Sun QF, Pan KH, Wang TY, Ma HL, Chen YP, Liu WY, George J, Zheng MH. Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. *Metabolism* 2020; **108**: 154244 [PMID: 32320741 DOI: 10.1016/j.metabol.2020.154244]
- Piedade J, Pereira G. COVID-19 in liver transplant recipients. *J Liver Transplant* 2021; **3**: 100026 [DOI: 10.1002/lt.14449]

- 10.1016/j.liver.2021.100026]
- 13 **Becchetti C**, Zambelli MF, Pasulo L, Donato MF, Invernizzi F, Detry O, Dahlqvist G, Ciccarelli O, Morelli MC, Fraga M, Svegliati-Baroni G, van Vlierberghe H, Coenraad MJ, Romero MC, de Gottardi A, Toniutto P, Del Prete L, Abbati C, Samuel D, Pirenne J, Nevens F, Dufour JF; COVID-LT group. COVID-19 in an international European liver transplant recipient cohort. *Gut* 2020; **69**: 1832-1840 [PMID: [32571972](#) DOI: [10.1136/gutjnl-2020-321923](#)]
  - 14 **Ali Malekhosseini S**, Nikoupour H, Gholami S, Shamsaeifar A, Arasteh P, Kazemi K, Dehghani M, Eghlimi H, Raeisi Shahraiki H, Roozbeh J, Rezaianzadeh A, Nikeghbalian S. A Report of 85 Cases of COVID-19 and Abdominal Transplantation From a Single Center: What Are the Associated Factors With Death Among Organ Transplantation Patients. *Transplantation* 2021; **105**: 90-99 [PMID: [32976364](#) DOI: [10.1097/TP.0000000000003470](#)]
  - 15 **Can E**, Oğlak SC, Ölmez F. Abnormal liver function tests in pregnant patients with COVID-19 - a retrospective cohort study in a tertiary center. *Ginekol Pol* 2022 [PMID: [35072238](#) DOI: [10.5603/GP.a2021.0182](#)]
  - 16 **Lei F**, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, Zhang XJ, Cai J, Lin L, Ouyang S, Wang X, Yang C, Cheng X, Liu W, Li H, Xie J, Wu B, Luo H, Xiao F, Chen J, Tao L, Cheng G, She ZG, Zhou J, Wang H, Lin J, Luo P, Fu S, Ye P, Xiao B, Mao W, Liu L, Yan Y, Chen G, Huang X, Zhang BH, Yuan Y. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. *Hepatology* 2020; **72**: 389-398 [PMID: [32359177](#) DOI: [10.1002/hep.31301](#)]
  - 17 **Fan Z**, Chen L, Li J, Cheng X, Yang J, Tian C, Zhang Y, Huang S, Liu Z, Cheng J. Clinical Features of COVID-19-Related Liver Functional Abnormality. *Clin Gastroenterol Hepatol* 2020; **18**: 1561-1566 [PMID: [32283325](#) DOI: [10.1016/j.cgh.2020.04.002](#)]
  - 18 **Phipps MM**, Barraza LH, LaSota ED, Sobieszczyk ME, Pereira MR, Zheng EX, Fox AN, Zucker J, Verna EC. Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort. *Hepatology* 2020; **72**: 807-817 [PMID: [32473607](#) DOI: [10.1002/hep.31404](#)]
  - 19 **Arima Y**, Yoshimoto K, Namera A, Makita R, Murata K, Nagao M. The Sarin-like Organophosphorus Agent bis (isopropyl methyl)phosphonate Induces Apoptotic Cell Death and COX-2 Expression in SK-N-SH Cells. *Hiroshima J Med Sci* 2016; **65**: 1-8 [PMID: [27348899](#)]
  - 20 **Chai X**, Hu L, Zhang Y, Han W, Lu Z, Ke A, Zhou J, Shi G, Fang N, Fan J, Cai J, Lan F. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. 2020 Preprint. Available from: bioRxiv: 2020.02.03.931766 [DOI: [10.1101/2020.02.03.931766](#)]
  - 21 **Zhou Z**, Zhao N, Shu Y, Han S, Chen B, Shu X. Effect of Gastrointestinal Symptoms in Patients With COVID-19. *Gastroenterology* 2020; **158**: 2294-2297 [PMID: [32199880](#) DOI: [10.1053/j.gastro.2020.03.020](#)]
  - 22 **Wijarnpreecha K**, Ungprasert P, Panjawanatanan P, Harnois DM, Zaver HB, Ahmed A, Kim D. COVID-19 and liver injury: a meta-analysis. *Eur J Gastroenterol Hepatol* 2021; **33**: 990-995 [PMID: [32639420](#) DOI: [10.1097/MEG.0000000000001817](#)]
  - 23 **Wu Y**, Guo C, Tang L, Hong Z, Zhou J, Dong X, Yin H, Xiao Q, Tang Y, Qu X, Kuang L, Fang X, Mishra N, Lu J, Shan H, Jiang G, Huang X. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. *Lancet Gastroenterol Hepatol* 2020; **5**: 434-435 [PMID: [32199469](#) DOI: [10.1016/S2468-1253\(20\)30083-2](#)]
  - 24 **Chau TN**, Lee KC, Yao H, Tsang TY, Chow TC, Yeung YC, Choi KW, Tso YK, Lau T, Lai ST, Lai CL. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. *Hepatology* 2004; **39**: 302-310 [PMID: [14767982](#) DOI: [10.1002/hep.20111](#)]
  - 25 **Payus AO**, Jeffrey MS, Ohn MH, Tan HJ, Ibrahim A, Chia YK, Raymond AA. Immune-mediated neurological syndrome in SARS-CoV-2 infection: a review of literature on autoimmune encephalitis in COVID-19. *Neurol Sci* 2022; **43**: 1533-1547 [PMID: [34853897](#) DOI: [10.1007/s10072-021-05785-z](#)]
  - 26 **Payus AO**, Jan T, Ibrahim A, Raymond AA. Autoimmune polyradiculopathy In SARS-CoV-2: a narrative review of Guillain-Barre syndrome in novel coronavirus disease (COVID-19). *Acta Med* 2020 [DOI: [10.19193/0393-6384\\_2020\\_6\\_599](#)]
  - 27 **Liu J**, Li S, Liu J, Liang B, Wang X, Wang H, Li W, Tong Q, Yi J, Zhao L, Xiong L, Guo C, Tian J, Luo J, Yao J, Pang R, Shen H, Peng C, Liu T, Zhang Q, Wu J, Xu L, Lu S, Wang B, Weng Z, Han C, Zhu H, Zhou R, Zhou H, Chen X, Ye P, Zhu B, Wang L, Zhou W, He S, He Y, Jie S, Wei P, Zhang J, Lu Y, Wang W, Zhang L, Li L, Zhou F, Wang J, Dittmer U, Lu M, Hu Y, Yang D, Zheng X. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine* 2020; **55**: 102763 [PMID: [32361250](#) DOI: [10.1016/j.ebiom.2020.102763](#)]
  - 28 **Alqahtani SA**, Schattenberg JM. Liver injury in COVID-19: The current evidence. *United European Gastroenterol J* 2020; **8**: 509-519 [PMID: [32450787](#) DOI: [10.1177/2050640620924157](#)]
  - 29 **Spearman CW**, Aghemo A, Valenti L, Sonderup MW. COVID-19 and the liver: A 2021 update. *Liver Int* 2021; **41**: 1988-1998 [PMID: [34152690](#) DOI: [10.1111/liv.14984](#)]
  - 30 **Li J**, Gong X, Wang Z, Chen R, Li T, Zeng D, Li M. Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan, China. *Virus Res* 2020; **286**: 198043 [PMID: [32502551](#) DOI: [10.1016/j.virusres.2020.198043](#)]
  - 31 **Zha BS**, Wan X, Zhang X, Zha W, Zhou J, Wabitsch M, Wang G, Lyall V, Hylemon PB, Zhou H. HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes. *PLoS One* 2013; **8**: e59514 [PMID: [23533630](#) DOI: [10.1371/journal.pone.0059514](#)]
  - 32 **Cao R**, Hu Y, Wang Y, Gurley EC, Studer EJ, Wang X, Hylemon PB, Pandak WM, Sanyal AJ, Zhang L, Zhou H. Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir *via* endoplasmic reticulum stress signaling pathways. *J Pharmacol Exp Ther* 2010; **334**: 530-539 [PMID: [20472667](#) DOI: [10.1124/jpet.110.168484](#)]
  - 33 **Ferrara F**, Granata G, Pelliccia C, La Porta R, Vitiello A. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? *Eur J Clin Pharmacol* 2020; **76**: 1615-1618 [PMID: [32594204](#) DOI: [10.1007/s00228-020-02947-4](#)]
  - 34 **Sun J**, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. *Liver Int* 2020; **40**: 1278-1281 [PMID: [32251539](#) DOI: [10.1111/liv.14470](#)]
  - 35 **Ghoda A**, Ghoda M. Liver Injury in COVID-19 Infection: A Systematic Review. *Cureus* 2020; **12**: e9487 [PMID:

- 32879813 DOI: [10.7759/cureus.9487](https://doi.org/10.7759/cureus.9487)]
- 36 **Yang L**, Wang W, Wang X, Zhao J, Xiao L, Gui W, Fan H, Xia J, Li Z, Yan J, Alasbahi A, Zhu Q, Hou X. Creg in Hepatocytes Ameliorates Liver Ischemia/Reperfusion Injury in a TAK1-Dependent Manner in Mice. *Hepatology* 2019; **69**: 294-313 [PMID: [30076625](https://pubmed.ncbi.nlm.nih.gov/30076625/) DOI: [10.1002/hep.30203](https://doi.org/10.1002/hep.30203)]
  - 37 **Xu Z**, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020; **8**: 420-422 [PMID: [32085846](https://pubmed.ncbi.nlm.nih.gov/32085846/) DOI: [10.1016/S2213-2600\(20\)30076-X](https://doi.org/10.1016/S2213-2600(20)30076-X)]
  - 38 **Ji D**, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. *J Hepatol* 2020; **73**: 451-453 [PMID: [32278005](https://pubmed.ncbi.nlm.nih.gov/32278005/) DOI: [10.1016/j.jhep.2020.03.044](https://doi.org/10.1016/j.jhep.2020.03.044)]
  - 39 **Liu Q**, Wang RS, Qu GQ, Wang YY, Liu P, Zhu YZ, Fei G, Ren L, Zhou YW, Liu L. Gross examination report of a COVID-19 death autopsy. *Fa Yi Xue Za Zhi* 2020; **36**: 21-23 [PMID: [32198987](https://pubmed.ncbi.nlm.nih.gov/32198987/) DOI: [10.12116/j.issn.1004-5619.2020.01.005](https://doi.org/10.12116/j.issn.1004-5619.2020.01.005)]
  - 40 **Sonzogni A**, Previtali G, Seghezzi M, Grazia Alessio M, Gianatti A, Licini L, Morotti D, Zerbi P, Carsana L, Rossi R, Lauri E, Pellegrinelli A, Nebuloni M. Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations. *Liver Int* 2020; **40**: 2110-2116 [PMID: [32654359](https://pubmed.ncbi.nlm.nih.gov/32654359/) DOI: [10.1111/liv.14601](https://doi.org/10.1111/liv.14601)]
  - 41 **Tian S**, Xiong Y, Liu H, Niu L, Guo J, Liao M, Xiao SY. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. *Mod Pathol* 2020; **33**: 1007-1014 [PMID: [32291399](https://pubmed.ncbi.nlm.nih.gov/32291399/) DOI: [10.1038/s41379-020-0536-x](https://doi.org/10.1038/s41379-020-0536-x)]
  - 42 **Rapkiewicz AV**, Mai X, Carsons SE, Pittaluga S, Kleiner DE, Berger JS, Thomas S, Adler NM, Charytan DM, Gasmfi B, Hochman JS, Reynolds HR. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. *EClinicalMedicine* 2020; **24**: 100434 [PMID: [32766543](https://pubmed.ncbi.nlm.nih.gov/32766543/) DOI: [10.1016/j.eclinm.2020.100434](https://doi.org/10.1016/j.eclinm.2020.100434)]
  - 43 **Wang XX**, Shao C, Huang XJ, Sun L, Meng LJ, Liu H, Zhang SJ, Li HJ, Lv FD. Histopathological features of multiorgan percutaneous tissue core biopsy in patients with COVID-19. *J Clin Pathol* 2021; **74**: 522-527 [PMID: [32848014](https://pubmed.ncbi.nlm.nih.gov/32848014/) DOI: [10.1136/jclinpath-2020-206623](https://doi.org/10.1136/jclinpath-2020-206623)]
  - 44 **Wang Y**, Liu S, Liu H, Li W, Lin F, Jiang L, Li X, Xu P, Zhang L, Zhao L, Cao Y, Kang J, Yang J, Li L, Liu X, Li Y, Nie R, Mu J, Lu F, Zhao S, Lu J, Zhao J. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. *J Hepatol* 2020; **73**: 807-816 [PMID: [32437830](https://pubmed.ncbi.nlm.nih.gov/32437830/) DOI: [10.1016/j.jhep.2020.05.002](https://doi.org/10.1016/j.jhep.2020.05.002)]
  - 45 **Wichmann D**, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Knierp I, Schröder AS, Burdelski C, de Heer G, Nierhaus A, Frings D, Pfefferle S, Becker H, Brederke-Wiedling H, de Weerth A, Paschen HR, Sheikhzadeh-Eggers S, Stang A, Schmiedel S, Bokemeyer C, Addo MM, Aepfelbacher M, Püschel K, Kluge S. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. *Ann Intern Med* 2020; **173**: 268-277 [PMID: [32374815](https://pubmed.ncbi.nlm.nih.gov/32374815/) DOI: [10.7326/M20-2003](https://doi.org/10.7326/M20-2003)]
  - 46 **Fix OK**, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. *Hepatology* 2020; **72**: 287-304 [PMID: [32298473](https://pubmed.ncbi.nlm.nih.gov/32298473/) DOI: [10.1002/hep.31281](https://doi.org/10.1002/hep.31281)]
  - 47 **Hambali NL**, Mohd Noh M, Paramasivam S, Chua TH, Hayati F, Payus AO, Tee TY, Rosli KT, Abd Rachman Isnadi MF, Manin BO. A Non-severe Coronavirus Disease 2019 Patient With Persistently High Interleukin-6 Level. *Front Public Health* 2020; **8**: 584552 [PMID: [33304877](https://pubmed.ncbi.nlm.nih.gov/33304877/) DOI: [10.3389/fpubh.2020.584552](https://doi.org/10.3389/fpubh.2020.584552)]
  - 48 **Sahin TT**, Akbulut S, Yilmaz S. COVID-19 pandemic: Its impact on liver disease and liver transplantation. *World J Gastroenterol* 2020; **26**: 2987-2999 [PMID: [32587443](https://pubmed.ncbi.nlm.nih.gov/32587443/) DOI: [10.3748/wjg.v26.i22.2987](https://doi.org/10.3748/wjg.v26.i22.2987)]
  - 49 **Henry BM**, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. *Clin Chem Lab Med* 2020; **58**: 1021-1028 [PMID: [32286245](https://pubmed.ncbi.nlm.nih.gov/32286245/) DOI: [10.1515/cclm-2020-0369](https://doi.org/10.1515/cclm-2020-0369)]
  - 50 **Kulkarni AV**, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, Talukdar R, Sharma M, Qi X, Rao PN, Reddy DN. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. *Aliment Pharmacol Ther* 2020; **52**: 584-599 [PMID: [32638436](https://pubmed.ncbi.nlm.nih.gov/32638436/) DOI: [10.1111/apt.15916](https://doi.org/10.1111/apt.15916)]
  - 51 **Gong J**, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, Cao J, Tan M, Xu W, Zheng F, Shi Y, Hu B. A Tool for Early Prediction of Severe Coronavirus Disease 2019 (COVID-19): A Multicenter Study Using the Risk Nomogram in Wuhan and Guangdong, China. *Clin Infect Dis* 2020; **71**: 833-840 [PMID: [32296824](https://pubmed.ncbi.nlm.nih.gov/32296824/) DOI: [10.1093/cid/ciaa443](https://doi.org/10.1093/cid/ciaa443)]
  - 52 **Huang J**, Cheng A, Kumar R, Fang Y, Chen G, Zhu Y, Lin S. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity. *J Med Virol* 2020; **92**: 2152-2158 [PMID: [32406952](https://pubmed.ncbi.nlm.nih.gov/32406952/) DOI: [10.1002/jmv.26003](https://doi.org/10.1002/jmv.26003)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

